S-1: Marpai Inc. Files for Resale of 3.9 Million Shares Following Nasdaq Delisting

Marpai Inc. has filed a registration statement for the resale of up to 3,943,334 shares of its common stock by selling stockholders, following its delisting from the Nasdaq Capital Market and transition to the OTCQX.

Summary

• Marpai Inc., a technology-driven healthcare Third Party Administrator (TPA), has filed a registration statement for the resale of up to 3,943,334 shares of its common stock.
• The shares are issuable upon the conversion of Senior Secured Convertible Debentures.
• The selling stockholders will offer these shares from time to time at prevailing market prices, and Marpai will not receive any proceeds from the sale.
• Marpai's common stock is now traded on the OTCQX Market under the symbol MRAI after being suspended from trading on Nasdaq effective May 29, 2024.
• The company withdrew from the Nasdaq hearings process due to non-compliance with the minimum stockholders' equity requirement.
• The last reported sale price of Marpai's Common Stock on OTCQX on May 29, 2024 was $0.65 per share.
• In April 2024, Marpai entered into a Securities Purchase Agreement to sell Senior Secured Convertible Debentures in an aggregate principal amount of $11,830,000 for a total purchase price of $11,000,000.
• The debentures bear interest at a rate equal to the prime interest rate plus 5.75% per annum, require monthly principal payments of $140,000 beginning on October 15, 2024, and have a maturity date of April 15, 2027.
• The conversion price of the debentures is $3.00 per share, subject to adjustment, but not below $2.23 per share.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is enabling resale of shares and continuing trading on OTCQX, the delisting from Nasdaq and associated risks weigh negatively on the overall sentiment.

Positives

• The registration allows selling stockholders to offer their shares in the public market, potentially providing liquidity.
• Marpai's transition to OTCQX ensures a trading market continues to exist for its securities after delisting from Nasdaq.

Negatives

• Marpai's delisting from Nasdaq due to non-compliance with listing requirements could negatively impact investor confidence.
• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The debentures contain covenants that restrict the Company from incurring additional indebtedness, creating or permitting liens on assets, amending its charter documents and bylaws, repurchasing or otherwise acquiring more than a de minimis number of its Common Stock or equivalents thereof, repaying outstanding indebtedness, paying dividends or distributions, assigning or selling certain assets, making or holding any investments, and entering into transactions with affiliates.

Risks

• An investment in Marpai's Common Stock involves significant risks, as detailed in the Risk Factors section of the prospectus.
• The value of Marpai's Common Stock could decline due to various risks, potentially leading to a loss of investment.
• There is no guarantee that a broker will continue to make a market in the Common Stock or that trading thereof will continue on OTCQX or otherwise.
• The company's failure to comply with Nasdaq listing requirements and subsequent delisting could adversely affect its business and operations.

Future Outlook

The company anticipates that the Nasdaq hearings panel will file a Form 25 with the Securities and Exchange Commission which will formally delist the Company's Common Stock from Nasdaq in the near term.

Industry Context

Marpai operates in the competitive healthcare Third Party Administrator (TPA) market, focusing on leveraging AI and data analytics to reduce healthcare costs for self-insured employers.

Comparison to Industry Standards

• Marpai's focus on AI-driven healthcare solutions aligns with the broader industry trend of digital health transformation.
• Companies like Accolade and Quantum Health also offer integrated healthcare solutions, but Marpai emphasizes AI and data analytics.
• The delisting from Nasdaq and transition to OTCQX is a setback compared to industry peers listed on major exchanges.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of debentures and the resale of shares.
• Employees may experience uncertainty due to the company's financial challenges and delisting.
• Clients may be concerned about the company's long-term stability and ability to provide services.

Next Steps

• The selling stockholders may offer and sell their shares of Common Stock from time to time.
• The Nasdaq hearings panel is expected to file a Form 25 to formally delist Marpai's Common Stock from Nasdaq.

Key Dates

Keywords

Marpai, Common Stock, OTCQX, Delisting, Debentures, Resale, Nasdaq, Healthcare, TPA, Securities